 |
Established in December of 2005, J-Pharma’s mission is to help mankind by creating and developing novel pharmaceuticals based upon a human-genomic approach; an approach where people with specific diseases are treated with novel and selective agents. J-Pharma’s intellectual property (IP) embraces the notion that cell membrane transporters are tightly associated to many diseases. In addition to drug molecules that target specific transporters, J-Pharma has discovered several important drug transporters within the human body that may be used to evaluate and optimize pharmacokinetics of new drug candidates. We believe that J-Pharma’s pipeline will lead to new agents and processes (i.e. diagnostic methods) and will increase the quality of life for an ageing population in industrialized countries. J-Pharma’s overall goal is to contribute globally to the maintenance of human health and improve human welfare through the creation of new drugs.
CEO of J-Pharma
Hitoshi Endou, M.D.. Ph.D. |
|
|
| Code |
Area |
Target |
Stage |
| JPH203 |
Cancer Therapeutics |
LAT1 |
Under preclinical, FPI est. in 2012 |
| JPH211 |
Cancer Diagnostics |
LAT1 |
Clinical trial completion |
| |
JPH211 works as a companion diagnostic with JPH203 |
| JPH367 |
Hyperuricemia |
URAT1 |
Under preclinical |
| JPH101 |
Hyperphosphatemia |
|
Preclinical completion |
|
|
|
| Material |
Transporters |
| L-type amino acid |
LAT1:SLC7A5, LAT2:SLC7A8, LAT3:SLC43A1, LAT4:SLC43A2 |
| Uric acid |
URAT1:SLC22A12, URATv1/GLUT9:SLC2A9, OAT10/URAT2:SLC22A13 |
| Organic anion |
OAT1:SLC22A5, OAT2:SLC22A7, OAT3:SLC22A8, OAT4:SLC22A11
OAT7:SLC22A9, OATN1:SLC22A13 |
| Testicular carnitine |
CT2:SLC22A16 |
| Others |
ASC-1:SLC7A10, Asc-2:SLC7a12, AGT1:SLC7A13 |
|
|
|
| Corporate name: |
J-Pharma Co., Ltd. |
| Founded: |
December 26, 2005 |
| Business scope: |
R&D, transporter-targeted therapeutic and diagnostic agents |
| Directors: |
Hitoshi Endou M.D., Ph.D (CEO)
Toshio Miyashita (CFO)
Hiroyuki Sakurai M.D., Ph.D
Michael F. Wempe Ph.D |
| Address: |
Shinjuku Hokuto bldg. 5F, 2-16-8 Shinjuku, Shinjuku-ku,
Tokyo 160-0022 Japan
Tel: +81-3-6240-1001 Fax: +81-3-3356-1003 |
| Affiliated company: |
Human Cell Systems Inc.(HCS) |
| Origin of the company name “J-Pharma”, |
We would like to deliver novel drugs to patients in the world by the technology of genomic drug discovery dispatched from Japan, and the abbreviated “J” represents such our hope. |
|
|
|
| 1993 |
Started basic researches on cell membrane transport proteins (transporter) at Kyorin University School of Medicine. |
| 1997-1998 |
Identified the cancer-specific target molecule of an essential amino acid transporter (LAT1) and acquired its intellectual property right. |
| 2001 |
Human Cell Systems Inc. was founded in Tokyo to support drug therapy strategy of “Starving tactics for cancer cells” targeting the cancer-specific molecule of LAT1.
Human Cell Systems Inc. is subsidiary of J-Pharma. |
| 2004 |
Concluded a license agreement with a pharmaceutical company on an anti-hyperuricemic agent, one of our pipelines. |
| 2005 |
Received a research grant on developing novel anti-pancreatic cancer agents targeting a new molecular from the organization of the Tokyo Joint Development Support Business
--- Research on the strategy of “Starving tactics for cancer cells” against pancreatic cancer.
J-Pharma Co., Ltd. was founded for global strategies of our pipeline development not only in Japan but also worldwide. |
| 2007-2009 |
Development project of antihyperphosphatemia agent
(Grant from National Institute of Biomedical innovation)
|
| 2008-2009 |
Development of therapeutic agent for gastric scirrhous cancer.
(Grant from New energy and Industrial Technology Development Organization)
|
| 2008-2010 |
Development project of a new molecule probe for PET targeting tumor-specific membrane proteins.
(Grant from Ministry of Education, Culture, Sports, Science and Technology)
|
| 2010-2012 |
Translational Research project on anticancer therapy using LAT1 and its selective inhibitor, JPH203
(Grant from New energy and Industrial Technology Development Organization)
|
|
|
|
